SCHEMBL2067657

SCHEMBL2067657

CCO[C]1NC=CC=C1NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
MEN1 O00255 2/20 0.41
CYP1A2 P05177 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 4/20 0.39
RAB9A P51151 1/20 0.38
MAPK8 P45983 3/20 0.37
ALDH1A1 P00352 2/20 0.36
RORC P51449 1/20 0.36
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PLK1 P53350 1/20 0.32
POLB P06746 1/20 0.32
TTK P33981 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067599 0.73 ALDH1A1 (0.33) KMT2ATDP1MEN1LMNAMAPT
SCHEMBL8397828 0.59 HSD17B10 (0.32) KMT2ATDP1MEN1CYP1A2LMNA
Phenacetin SCHEMBL23280 0.59 KMT2A (1.00) KMT2ATDP1MEN1CYP1A2LMNA
Phenacetin SCHEMBL18894356 0.59 KMT2A (1.00) KMT2ATDP1MEN1CYP1A2LMNA
SCHEMBL3403700 0.59 KMT2A (0.51) KMT2ATDP1MEN1CYP1A2LMNA
SCHEMBL457546 0.58 TDP1 (0.51) KMT2ATDP1MEN1CYP1A2LMNA
Phenacetin SCHEMBL10630698 0.58 KMT2A (0.96) KMT2ATDP1MEN1CYP1A2LMNA
SCHEMBL11330858 0.58 MAPT (0.55) KMT2ATDP1MEN1CYP1A2LMNA
Phenacetin SCHEMBL28630552 0.58 KMT2A (0.96) KMT2ATDP1MEN1CYP1A2LMNA
Phenacetin SCHEMBL28388594 0.58 KMT2A (0.96) KMT2ATDP1MEN1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 KMT2A 986/4885TDP1 2578/4885MEN1 2864/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 KMT2A 1019/4885TDP1 2676/4885MEN1 3285/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 KMT2A 1019/4885TDP1 2676/4885MEN1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.